A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Colorectal Cancer (Diagnosis) · Colorectal Cancer Metastatic · Colorectal Cancer (CRC) · Immunotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Liverpool Cancer Therapy Centre, Liverpool, New South Wales, Australia

  • Macquarie University Hospital (MUH), Macquarie Park, New South Wales, Australia

  • Scientia Clinical Research, Randwick, New South Wales, Australia

  • Greenslopes Private Hospital - Cyril Gilbert Cancer Centre, Greenslopes, Queensland, Australia

  • The Queen Elizabeth Hospital (TQEH), Woodville South, South Australia, Australia

  • Monash University - Faculty of Medicine, Nursing and Health Sciences, Clayton, Victoria, Australia

  • Austin Health - Cancer Clinical Trials Centre (CCTC), Heidelberg, Victoria, Australia

  • Linear Clinical Research, Nedlands, Western Australia, Australia

  • Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

  • E-Da Cancer Hospital, Kaohsiung City, Taiwan

  • Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

  • Taipei Medical University Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan

  • National Cheng Kung University Hospital, Tainan, Taiwan

  • National Taiwan University Hospital - Cancer Center, Taipei, Taiwan

  • Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan